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Abstract
Background: The objectives of the present study are to investigate the efficacy and safety profile of gemcitabine-
based combinations in the treatment of locally advanced and metastatic pancreatic adenocarcinoma (LA/MPC).
Methods: We performed a computerized search using combinations of the following keywords: “chemotherapy”,
“gemcitabine”, “trial”, and “pancreatic cancer”.
Results: Thirty-five trials were included in the present analysis, with a total of 9,979 patients accrued. The analysis
showed that the gemcitabine-based combination therapy was associated with significantly better overall survival
(OS) (ORs, 1.15; p = 0.011), progression-free survival (PFS) (ORs, 1.27; p < 0.001), and overall response rate (ORR)
(ORs, 1.58; p < 0.001) than gemcitabine monotherapy. Similar results were obtained when the gemcitabine-
fluoropyrimidine combination was compared with gemcitabine, with the OS (ORs, 1.33; p = 0.007), PFS (ORs, 1.53;
p < 0.001), and ORR (ORs 1.47, p = 0.03) being better in the case of the former. The OS (ORs, 1.33; p = 0.019), PFS
(ORs, 1.38; p = 0.011), and one-year survival (ORs, 1.40; p = 0.04) achieved with the gemcitabine-oxaliplatin
combination were significantly greater than those achieved with gemcitabine alone. However, no survival benefit
(OS: ORs, 1.01, p = 0.93; PFS: ORs, 1.19, p = 0.17) was noted when the gemcitabine-cisplatin combination was
compared to gemcitabine monotherapy. The combinations of gemcitabine and other cytotoxic agents also
afforded disappointing results. Our analysis indicated that the ORR improved when patients were treated with the
gemcitabine-camptothecin combination rather than gemcitabine alone (ORs, 2.03; p = 0.003); however, there were
no differences in the OS (ORs, 1.03; p = 0.82) and PFS (ORs, 0.97; p = 0.78) in this case.
Conclusions: Gemcitabine in combination with capecitabine or oxaliplatin was associated with enhanced OS and
ORR as compared with gemcitabine in monotherapy, which are likely to become the preferred standard first-line
treatment of LA/MPC.
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Background
Pancreatic adenocarcinoma is the fifth leading cause of
death due to solid tumors in Western industrialized
countries. Because pancreatic adenocarcinoma is often
difficult to detect in early stages, most patients are diag-
nosed with advanced or metastatic disease at first pre-
sentation [1,2]. The median survival of patients with
locally advanced disease is 6 to 10 months, compared to
3 to 6 months for patients with metastatic disease [3].
Gemcitabine (Gemzar™;2 ’,2’-difluorodeoxycytidine) is
a pyrimidine antimetabolite and a specific analogue of
deoxycytidine. At present, gemcitabine monotherapy
remains the standard care for patients with locally
advanced and metastatic pancreatic adenocarcinoma
(LA/MPC) [4]. However, patients who receive this
therapy have a median overall survival (OS) of only
5.65 months [5]. In an effort to increase the objective
response rate (RR) and survival of LA/MPC patients,
many trials have been carried out in the last ten years to
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apy regimens. Currently, the National Comprehensive
Cancer Network (NCCN) guidelines indicate that gemci-
tabine combined with one other agent is the optimal
treatment for LA/MPC patients with evidence of cate-
gory 2B disease (recommendation based on lower-level
evidence).
It is unclear whether this regimen is the ideal treat-
ment for LA/MPC or whether it should be reevaluated.
Therefore, we undertook a systematic review and quan-
titative meta-analysis to evaluate the available evidence
from relevant randomized trials. This review will sum-
marize the various trials of gemcitabine-based che-
motherapy regimens in LA/MPC and discuss how these
results should affect clinical practice.
Methods
Search strategy
We carried out a comprehensive search of the literature
for randomized controlled trials in Pubmed using the
terms “chemotherapy,”“ gemcitabine,”“ trials,” and “pan-
creatic cancer” (no limitation for language). In addition
to full publications, abstracts presented at the annual
meetings of the American Society of Clinical Oncology
(ASCO) and the European Cancer Conference (ECCO)
were included.
Selection criteria
To be eligible for inclusion, trials were required to be
prospective, properly randomized and well designed,
which we defined as matched for age, stage and perfor-
mance status (PS) or Karnofsky performance status
(KPS). Patients with locally advanced or metastatic dis-
ease were included in the study, and histologic or cyto-
logic confirmation of pancreatic adenocarcinoma was
required.
If a trial included concomitant interventions such as
radiotherapy or radioisotope treatment that differed sys-
tematically between the investigated arms, the trial was
excluded. Whenever we encountered reports pertaining
to overlapping patient populations, we included only the
report with longest follow-up (having the largest num-
ber of events) in the analysis. Only randomized trials
were included, and randomization must have started on
or after Jan 1, 1965. The deadline for eligible trial publi-
cation was July 30, 2010.
Data collection
Two reviewers (Jing Hu and Gang Zhao) assessed the
identified abstracts. Both reviewers independently
selected trials for inclusion according to prior agreement
regarding the study population and intervention. Lei
Tang and Ying-Chun Xu also cross-checked all data col-
lected against the original articles. If one of the
reviewers determined that an abstract was eligible, the
full text of article was retrieved and reviewed in detail
by all reviewers.
For the 35 trials included in the meta-analysis, we
gathered the authors’ names, journal, year of publica-
tion, sample size (randomized and analyzed) per arm,
performance status, regimens used, line of treatment,
median age of patients and information pertaining to
study design (whether the trial reported the mode of
randomization, allocation concealment, description of
withdrawals per arm and blinding).
Statistical analysis
The meta-analysis was performed using Review Manager
Version 4.2 (Nordic Cochran Centre, Copenhagen) and
Comprehensive Meta Analysis Version 2 (Biostat™,
Englewood, NJ). Heterogeneity between the trials was
assessed to determine which model should be used. To
assess statistical heterogeneity between studies, the
Cochran Q test was performed with a predefined signifi-
cance threshold of 0.05. Odds ratios (ORs) were the
principal measurements of effect and were presented
with a 95% confidence interval (CI). P values of < 0.05
were considered statistically significant. All reported p-
values result from two-sided versions of the respective
tests. The revision of funnel plots did not reveal any
considerable publication bias.
The primary outcome measurements were overall survi-
val (OS) and progression-free survival (PFS, time from
randomization to progression or death), and secondary
endpoints were overall response rate (ORR, number of
partial and complete responses) and toxicity. Toxicities
recorded by the original research group were recorded in
our analysis, and the most frequent events were analyzed.
In order to optimize our assessment of response, we used
trials that included patients with measurable or assessable
diseases and that were analyzed predominantly according
to the World Health Organization (WHO) criteria. Toxi-
city profiles were reported according to the WHO criteria.
Results
Selection of the trials
The literature search uncovered 762 articles. Primary
screening led to the exclusion of 390 articles for the fol-
lowing reasons: reviews (218), other agents/regimens
(43), radiotherapy/chemoradiation (99), letters/com-
ments/editorials [26] or case reports [4]. The remaining
372 papers were retrieved for more detailed evaluation.
Of these, 144 articles were excluded because of adjuvant
chemotherapy, 44 for biliary tract cancer, 110 for phase
I clinical trials, 38 for not-controlled design and 2 for
repeated reports [6,7]. In the end, a total of 35 rando-
mized clinical trials [8-42] were eligible for inclusion in
our analysis (Figure 1).
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Thirty-five trials were included in the present analysis,
with a total of 9, 979 patients accrued. Characteristics of
the eligible trials are listed in Table 1. Most of the trials
(34/35, 97%) evaluated gemcitabine-based chemotherapy
for first line or palliative chemotherapy in LA/MPC
patients, whereas one trial (Palmer 2007) evaluated
neoadjuvant chemotherapy. Twenty-three trials com-
pared single-agent gemcitabine with gemcitabine com-
bined with other cytotoxic agents, nine trials studied
gemcitabine monotherapy with gemcitabine plus tar-
geted therapy, and three trials evaluated triplet therapy
for LA/MPC patients.
Among the thirty-five trials, the distribution of baseline
patient characteristics was homogeneous. The percentage
of patients with metastatic disease ranged from 50% to
91.1%, while the median age of patients varied from 57.8
to 66 (range: 23-96). The details of chemotherapeutic
regimens per arm in each trial are shown in Table 2.
Trials comparing single-agent gemcitabine with
gemcitabine combined with other cytotoxic agents
This analysis evaluated 23 trials (5,577 patients) compar-
ing single-agent gemcitabine with gemcitabine-based
combinations with other cytotoxic agents. For the pri-
mary endpoint of OS, the gemcitabine-based combina-
tion therapy was associated with significantly better
outcome (ORs, 1.15; 95% CI, 1.03-1.28; p = 0.011) than
gemcitabine in monotherapy (Figure 2A). The analysis
of PFS also afforded favorable results for the combina-
tion arm, with the ORs being 1.27 (95% CI, 1.14-1.42;
p < 0.001) (Figure 2B). A similar advantage for gemcita-
bine-based combinations was observed in terms of the
ORR (ORs, 1.58; 95% CI, 1.31-1.91; p < 0.001), with no
significant heterogeneity (p = 0.79).
Trials comparing gemcitabine alone with gemcitabine
plus fluoropyrimidine
Six studies involving 1829 patients (Cunningham 2009,
Bernhard 2008, Scheithauer 2003, Berlin 2004, Di Costanzo
2005, Riess 2005) compared single agent gemcitabine with
gemcitabine plus fluoropyrimidine. Both oral capecitabine
and infused 5-fluorouracil (5-FU) were evaluated in combi-
nation with gemcitabine in a variety of dosing schedules in
these studies.
Our analysis showed a significant improvement in OS
(ORs, 1.33; 95% CI, 1.08 to 1.64; p = 0.007) (Figure 3A),
PFS (ORs, 1.53; 95% CI, 1.24 to 1.88; p = 0.000) and
ORR (ORs, 1.47; 95% CI, 1.04 to 2.07; p = 0.03) when
gemcitabine was combined with fluoropyrimidine. The
ORs for 1-year survival in the gemcitabine plus fluoro-
pyrimidine group as compared with the group that
received gemcitabine alone was 1.08 (95% CI, 0.82 to
1.43; p = 0.58).
Trials comparing gemcitabine alone with gemcitabine
plus platinum
The combination of gemcitabine with platinum was evalu-
ated in eleven trials involving 2,379 patients. Three trials
used oxaliplatin (Louvet 2005, Poplin 2009, Yan 2007),
and eight trials (Colucci 2010, Colucci 2002, Wang 2002,
Heinemann 2006, Palmer 2007, Li 2004, Kulke 2009, Viret
2004) used cisplatin combined with gemcitabine. In these
trials, the gemcitabine/platinum combinations prolonged
OS in nine trials, whereas no survival benefit was seen in
two trials (Colucci 2010, Wang X 2002).
Meta-analysis showed that the combination of gemci-
tabine with platinum resulted in a significant improve-
ment in PFS (ORs, 1.29; 95% CI, 1.08 to 1.54; p = 0.005)
(Figure 3E) as compared with gemcitabine in monother-
apy, though no statistical significant difference in OS
was observed (ORs, 1.16; 95% CI, 0.98 to 1.38; p = 0.08)
(Figure 3B). When ORR was compared, the platinum
combination arm showed significantly higher disease
control, which was reflected by a pooled ORs of 1.48
(95% CI, 1.15 to 1.92; p = 0.002) in favor of the plati-
num combination (Figure 4C.).
Subgroup analysis comparing the gemcitabine/oxali-
platin group with the gemcitabine alone group gave an
ORs of 1.33 (95% CI, 1.05 to 1.69) for OS and ORs of
1.38 (95% CI, 1.08 to 1.76) for PFS, which was statisti-
cally significant (p = 0.019, p = 0.011, seperately) in
favor of gemcitabine/oxaliplatin combination (Figure 3C,
F). However, the comparison of gemcitabine/cispiatin
with gemcitabine alone showed that there was no survi-
val benefit (OS: ORs, 1.01, p = 0.93; PFS: ORs, 1.19, p =
0.17) (Figure 3D, G). There was also a trend toward to
increased ORR in the gemcitabine/cisplatin combination
versus gemcitabine alone, with a pooled ORs of 1.38
(95% CI, 1.00 to 1.91), but the difference was not signifi-
cant (p = 0.05). With regards to one-year survival, we
did not find a difference between the gemcitabine/plati-
num group versus gemcitabine alone (OR, 1.15; 95% CI,
0.92 to 1.44; p = 0.22) (Figure 4A), but there was a
Figure 1 Flow chart for trials selection in the meta-analysis.
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Trial No. of pts Regimens
(per arm)
No. of pts
(per arm)
Male Median age
(range)(y)
PS 0-2/KPS≥50 M*
Gong JF 40 palliative Gem-X** 25 56% 63 (45-76) UK UK
2007[8] Gem 15 66.7% 63 (45-76)
Reni M 104 first line PEFG 52 46.2% 62 (37-69) 100% 71%
2005[9] Gem 47 40.7% 59 (25-69) 100% 56%
Gem versus Gem plus fluoropyrimidine
Cunningham D 533 first line Gem/Cap 267 60% 62 (37-82) 100% 70%
2009[10] Gem 266 58% 62 (26-83) 100% 71%
Bernhard J 319 palliative Gem/Cap 160 54% 62 (27-83) 100% 80%
2008[11] Gem 159 53% 62 (36-84) 100% 79%
Scheithauer W 83 first line Gem/Cap 41 66% 64 (40-75) 100% UK
2003[12] Gem 42 55% 66 (39-75) 100%
Berlin JD 327 first line Gem/5-FU 160 51.8% 65.8 (28-84) 100% 89.4%
2002[13] Gem 162 53.7% 64.3 (33-85) 100% 90.1%
Di Costanzo F 94 first line Gem/5-FU 45 63% 62 (44-75) 100% 67%
2005[14] Gem 49 48% 64 (34-75) 100% 73%
Riess H[] 473 first line Gem/5-FU 235 UK UK 100% UK
2005 Gem 238 100%
Gem versus Gem plus platinum
Louvet C 313 first line Gem/Oxa 157 60% 61 (35-77) 100% 68%
2005[16] Gem 156 53% 60 (22-75) 100% 70%
Poplin E 824 first line Gem/Oxa 272 45.6% 63 (29-96) 99.6% 89.3%
2009[17] Gem 275 56.4% 63 (31-88) 100% 90.2%
Gem FDR 277 57.8% 62 (36-87) 99.6% 88.8%
Yan ZC 60 first line Gem/Oxa 30 63.3% 58 (23-75) 31.7% UK
2007[18] Gem 30 63.3% 58 (23-75) 31.7% UK
Colucci G 400 first line Gem/DDP 201 62.2% 63 (35-75) 100% 84.6%
2010[19] Gem 199 56.8% 63 (37-75) 100% 82.9%
Colucci G 107 first line Gem/DDP 53 66% 60 (33-71) 100% 62%
2002[20] Gem 54 50% 63 (43-75) 100% 54%
Wang XY 42 first line Gem/DDP 22 68.2% 65 (37-76) 100% 68.2%
2002[21] Gem 20 70.0% 57 (35-60) 100% 50%
Heinemann V 195 first line Gem/DDP 98 65.3% 64 (37-82) 100% 80%
2006[22] Gem 97 61.9% 66 (43-85) 100% 78.9%
Palmer DH 50 neoadjuvant Gem/DDP 26 50% 66 (47-78) 100% UK
2007[23] Gem 24 54% 66 (40-79) 100%
Li CP 46 first line Gem/DDP 21 UK UK UK UK
2004[24] Gem 25
Kulke MH 259 first line Gem/DDP 66 56% 59 (36-84) 100% UK
2009[25] Gem FDR 64 66% 59 (31-81) 100% UK
Gem/Doc 65 62% 63 (41-79) 100% UK
Gem/CPT-11 64 68% 61 (32-77) 100% UK
Viret F 83 first line Gem/DDP 42 UK 62 100% 81%
2004[26] Gem 41 UK 63 100% 78%
Gem versus camptothecin
Stathopoulos GP 130 first line Gem/CPT-11 60 65% 64 (31-84) 100% 78%
2006[27] Gem 70 60% 64 (44-83) 100% 86%
Rocha Lima CM 360 first line Gem/CPT-11 180 57.2% 63 (39-81) 97.2% 82.2%
2004[28] Gem 180 53.3% 60 (32-83) 93.9% 80.6%
Abou-Alfa GK 349 first line Gem/exatecan 175 53% 63 (36-85) 99% 79%
2006[29] Gem 174 57% 62 (30-84) 100% 78%
Hu et al. Journal of Hematology & Oncology 2011, 4:11
http://www.jhoonline.org/content/4/1/11
Page 4 of 15significant improvement in the gemcitabine/oxaliplatin
group (OR, 1.40; 95% CI, 1.02 to 1.93; p = 0.04) in the
subgroup analysis (Figure 4B).
One trial (Palmer 2007) compared gemcitabine plus
cisplatin with gemcitabine in the neoadjuvant setting.
The study showed that the percentage of patients who
underwent resection was 38% in gemcitabine arm versus
70% in the combination arm, with no increase in surgi-
cal complications. The 12-month survival percentages
for the gemcitabine and combination groups were 42%
and 62%, respectively. Combination therapy with gemci-
tabine and cisplatin was associated with a higher resec-
tion rate and an encouraging survival rate, suggesting
that further study is warranted.
Trials comparing gemcitabine alone with gemcitabine
plus camptothecin
Four randomized trials (n = 839) compared the combi-
nation of gemcitabine and topoisomerase I inhibitors
(irinotecan or exatecan) with gemcitabine monotherapy.
They included three studies (Kulke 2009, Stathopoulos
2006, Rocha Lima 2004) in which gemcitabine was com-
bined with CPT-11 (irinotecan) and one study (Abou-
Alfa 2006) in which gemcitabine was combined with
exatecan. The analysis revealed a significant improve-
ment in ORR for gemcitabine plus camptothecin ther-
apy (ORs 2.03; 95% CI, 1.28 to 3.23; p = 0.003;
heterogeneity, p = 0.14). However, the combination did
not significantly improve OS or PFS. The pooled ORs
for OS and PFS were 1.03 (95% CI, 0.81 to 1.32; p =
0.82) and 0.97 (95% CI, 0.76 to 1.23; p = 0.78), respec-
tively (Figure 5).
Trials comparing gemcitabine monotherapy with
gemcitabine plus other agents
Various other cytotoxic agents have been tested in com-
bination with gemcitabine in LA/MPC patients, includ-
ing pemetrexed (Alimta) and docetaxel. The analysis
included two trials (n = 665), which indicated that the
OS in the combination group was even lower than
Table 1 Characteristics of the eligible trials included in the meta-analysis (Continued)
Gem versus pemetrexed
Oettle H 565 palliative Gem/Pem* 283 60.4% 63 (27-82) 98.9% 90.1%
2005[30] Gem 282 53.5% 63 (28-82) 98.9% 91.1%
Gem versus Gem plus targeted therapy
Moore MJ 569 palliative Gem/erlotinib 285 47.7% 64 (38-84) 99.6% 76.5%
2007[31] Gem 284 57% 64 (36-92) 100% 75%
Van Cutsem E 688 first line Gem/tipifarnib 341 57% 61 (29-89) 100% 76%
2004[32] Gem 347 58% 62 (30-88) 100% 77%
Philip PA 743 palliative Gem/Cetuximab 372 51% 63.7 100% 79%
2010[33] Gem 371 54% 64.3 100% 78%
Saif MW 135 palliative Gem/LY293111 67 60% 62(33-82) 99% 87%
2009[34] Gem 66 60% 62(34-85) 99% 90%
Spano JP 103 palliative Gem/axitinib 69 51% 65(44-81) 100% 58%
2008[35] Gem 34 47% 61(36-78) 100% 56%
Bramhall SR 239 first line Gem/marimastat 120 57.5% 62 (32-83) 100% 59%
2002[36] Gem 119 59.7% 62 (37-85) 100% 62%
Kindler HL 602 first line Gem/Bev 302 58% 64 (26-88) 100% 84%
2010[37] Gem 300 51% 65 (35-86) 100% 85%
Richards DA 174 first line Gem/CI-994 86 59.3% 62 (32-82) 100% 82.6%
2006[38] Gem 88 60.2% 65 (36-83) 100% 83%
Friess H 89 first line Gem/Cilengitide 46 57% 68 (40-80) 100% 93%
2006[39] Gem 43 42% 66 (56-80) 100% 90%
the others
Cascino S 84 first line C-225/Gem/DDP 42 69% 61 (38-78) 100% 73.8%
2008[40] Gem/DDP 42 52% 64 (40-76) 100% 71.4%
Vervenne W 607 first line Gem/erlotinib/Bev 306 57% 62 100% 100%
2008[41] Gem/erlotinib 301 62% 61 100% 100%
Boeck S 190 first line Cap/Oxa 61 65% 62 (37-74) 100% 63%
2007[42] Gem/Cap 64 57% 63 (47-75) 100% 69%
Gem/Oxa 63 70% 63 (45-75) 100% 71%
Note: Gem, gemcitabine; DDP, cisplatin; C-225, Cetuximab; Bev, bevacizumab; Oxa, oxaliplatin; Cap, capecitabine; Doc, docetaxel; FDR, fixed dose rate; UK,
unknown; M*, metastatic disease; Gem-X, gemcitabine combined with 5-FU or capecitabine or cisplatin or oxaliplatin.
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Trial Arm Regimens
Gong JF 2007 Gem/X Gem 1,000 mg/m
2 d1,8; 5-FU 425-600 mg/m
2 d1-5, or DDP 30-37.5 mg/m
2 d1-2, or Oxa 85-130 mg/m
2 d1, or Cap 1
000 mg/m
2 bid d1-14, q3w.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
Reni M 2005 PEFG DDP 40 mg/m
2 d1, EPI 40 mg/m
2 d1, Gem 600 mg/m
2 d1,8, 5-FU 200 mg/m
2 d1-28, q4w.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
Gem versus Gem plus fluoropyrimidine
Cunningham D Gem/Cap Gem 1,000 mg/m
2 weekly for 3 weeks; Cap 830 mg/m
2 bid po for 3 weeks, q4w
2009 Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Bernhard J 2008 Gem/Cap Gem 1,000 mg/m
2 d1,8; Cap 650 mg/m
2 bid po d1-14, q3w.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Scheithauer Gem/Cap Gem 2200 mg/m
2 d1, Cap 2500 mg/m
2 d1-7, q2w.
W 2003 Gem Gem 2200 mg/m
2 d1, q2w.
Berlin JD 2002 Gem/5-FU Gem 1,000 mg/m
2 weekly, 5-FU 600 mg/m
2 weekly for 3 weeks, q4w.
Gem Gem 1,000 mg/m
2 weekly for 3 weeks, q4w.
Di Costanzo Gem/5-FU Gem was combined with 5-FU 200 mg/m
2 for 6 weeks in the first cycle, followed by a week of rest; then for 3
weeks, q4w.
F 2005 Gem Gem 1,000 mg/m
2 weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
Riess H 2005 GFF Gem 1,000 mg/m
2, 5-FU 750 mg/m
2, folinic acid 200 mg/m
2 d1,8,15,22, q6w.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
Gem versus Gem plus platinum
Louvet C 2005 Gem/Oxa Gem 1,000 mg/m
2 d1, Oxa 100 mg/m
2 d2, q2w.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Poplin E 2009 Gem/Oxa Gem 1,000 mg/m
2 d1, Oxa100 mg/m
2 d2, q2w.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Gem FDR Gem 1,500 mg/m
2 administered as a 150 minutes infusion d1,8,15, q4w.
Yan ZC 2007 Gem/Oxa Gem 1,000 mg/m
2 d1, Oxa 100 mg/m
2 d2, q2w.
Gem Gem 1,000 mg/m
2 d1,8,15, q4w.
Colucci G 2010 Gem/DDP Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; DDP 25 mg/m
2 added
weekly to Gem.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Colucci G 2002 Gem/DDP Gem 1000 mg/m
2 weekly × 7 followed by 2-week rest, DDP 25 mg/m
2 per week 1 hour before Gem.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 2-week rest, then weekly for 3 weeks, q4w.
Wang XY 2002 Gem/DDP Gem 1 000 mg/m
2 d1,8,15; DDP 60 mg/m
2 on d15, q4w.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Heinemann V
2006
Gem/DDP Gem 1,000 mg/m
2, DDP 50 mg/m
2 d1,15, q4w.
Gem Gem 1,000 mg/m
2 d1,8,15, q4w.
Palmer DH 2007 Gem/DDP Gem 1000 mg/m
2 every 7 days for 43 days, followed immediately by DDP 25 mg/m
2
Gem Gem 1000 mg/m
2 every 7 days for 43 days
Li CP 2004 Gem/DDP Gem 1000 mg/m
2/week and DDP 25 mg/m
2/week × 3 every 4 weeks
Gem Gem 1000 mg/m
2 × 3 every 4 weeks
Kulke MH 2009 Gem/DDP Gem 1,000 mg/m
2 d1,8,15; DDP 50 mg/m
2 d1,15, q4w.
Gem FDR Gem 1,500 mg/m
2 at a rate of 10 mg/m
2/min d1,8,15, q4w.
Gem/Doc Gem 1,000 mg/m
2; Doc 40 mg/m
2 d1,8, q3w.
Gem/CPT-11 Gem 1,000 mg/m
2; irinotecan 100 mg/m
2 d1,8, q3w.
Viret F 2004 Gem/DDP Gem 1000 mg/m
2 d1,8,15; DDP 75 mg/m
2 d15, q4w.
Gem Gem 1000 mg/m
2 weekly × 7 followed by 1 week of rest, then weekly for 3 weeks, q4w
Gem versus camptothecin
Stathopoulos GP
2006
Gem/CPT-11 Gem d1,8; CPT-11 300 mg/m
2 d8, q3w.
Gem Gem 900 mg/m
2 d1,8,15, q4w.
Rocha Lima CM
2004
Gem/CPT-11 Gem 1,000 mg/m
2 and CPT-11 100 mg/m
2 given weekly for 2 weeks every 3-week cycle.
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-0.04; p = 0.002), although the ORR analysis showed
therapeutic benefit of the combination (ORs, 1.91; 95%
CI, 1.16 to 3.16; p = 0.01) (Figure 5B).
Oettle’s trial, a randomized phase III study with 565
patients comparing the combination of gemcitabine and
pemetrexed to gemcitabine alone, showed that OS was
not improved in the combination arm (6.2 months) com-
pared with the gemcitabine alone group (6.3 months)
(p = 0.8477), although tumor response rate (14.8% versus
7.1%; p = 0.004) was significantly better in the combina-
tion arm.
Trials comparing gemcitabine monotherapy with
gemcitabine plus targeted therapy
The role of new, targeted drugs in the treatment of
advanced pancreatic adenocarcinoma has been actively
explored in the past few years. There are preliminary
Table 2 Regimens of the trials included in this analysis (Continued)
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Abou-Alfa GK
2006
Gem/Exat Exatecan 2.0 mg/m
2 and Gem 1,000 mg/m
2 were administered on days 1 and 8, q3w.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Gem versus pemetrexed
Oettle H 2005 Gem/Pem Gem 1,250 mg/m
2 d1,8; pemetrexed 500 mg/m
2 d8, q3w.
Gem Gem 1,000 mg/m
2 d1,8,15, q4w.
Gem versus Gem plus targeted therapy
Moore MJ 2007 Gem/Erlo Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; Erlotinib 100 or 150 mg/d
po
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w
Van Cutsem E
2004
Gem/Tipi Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; Tipifarnib 200 mg bid po
continuously;
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w
Philip PA 2010 Gem/C-225 Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w;
Cetuximab 400 mg/m
2 on week 1, followed by weekly 250 mg/m
2.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w
Saif MW 2009 Gem/LY Gem 1000 mg/m
2 d1,8,15, q4w; continuously administered LY 600 mg twice daily.
Gem Gem 1000 mg/m
2 d1,8,15, q4w.
Spano JP 2008 Gem/Axitinib Gem 1000 mg/m
2 d1,8,15, q4w; Axitinib 5 mg twice daily.
Gem Gem 1000 mg/m
2 d1,8,15, q4w.
Bramhall SR 2002 Gem/
Marimastat
Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; Marimastat 25 mg bid po.
Gem Gem 1,000 mg/m
2 weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
Kindler HL 2010 Gem/Bev Gem 1,000 mg/m
2 d1,8,15; Bev 10 mg/kg d1,15; q4w.
Gem Gem 1,000 mg/m
2 d1,8,15; q4w.
Richards DA 2006 Gem/CI-994 Gem 1000 mg/m
2 d1,8,15; CI-994 6 mg/m
2 d1-21; q4w.
Gem Gem 1000 mg/m
2 d1,8,5; q4w.
Friess H 2006 Gem/Cile Gem 1000 mg/m
2 d1,8,15; Cilengitide 600 mg/m
2 twice weekly; q3w.
Gem Gem 1000 mg/m
2 d1,8,15; q3w.
the others
Cascino S 2008 C-225/Gem/
DDP
Cetuximab 250 mg/m
2 weekly, after a loading dose of 400 mg/m2; Gem 1000 mg/m
2 and DDP 35 mg/m
2 on
d1,8; q3w.
Gem/DDP Gem 1000 mg/m
2 and DDP 35 mg/m
2 on d1,8; q3w.
Vervenne W 2008 Gem/Erlo/
Bev
Gem 1,000 mg/m
2 weekly × 7 during first 8 weeks, then for 3 weeks, q4w.
Erlotinib 100 mg/d po daily; Bevacizumab 5 mg/kg q2w.
Gem/Erlo Gem 1,000 mg/m
2 weekly × 7 for 7 weeks followed by 1-week rest, then weekly for 3 weeks, q4w; Erlotinib 100
mg/d po daily.
Boeck S 2007 Cap/Oxa Cap 1000 mg/m
2 bid d1-14; Oxa 130 mg/m
2 d1.
Gem/Cap Gem 1,000 mg/m
2 d1,8; Cap 825 mg/m
2 bid d1-14
Gem/Oxa Gem 1,000 mg/m
2 d1,8; Oxa 130 mg/m
2 d8
Note: Gem, gemcitabine; DDP, cisplatin; 5-FU, 5-fluorouracil; EPI, epirubicin; CPT-11, irinotecan; Bev, bevacizumab; Oxa, oxaliplatin; Cap, capecitabine; Doc,
docetaxel; FDR, fixed dose rate; Exat, exatecan; Tipi, tipifarnib; Erlo, Erlotinib; C-225, cetuximab; Cile, Cilengitide; Bev, bevacizumab; LY, LY293111; UK, unknown;
M*, metastatic disease; Gem-X, gemcitabine combined with 5-FU or capecitabine or cisplatin or oxaliplatin.
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Page 7 of 15results and ongoing studies with EGFR inhibitors (erloti-
nib, cetuximab), farnesyltransferase inhibitors (tipifar-
nib), leukotriene B4 receptor antagonists (LY293111),
antiangiogenic agents (axitinib, cilengitide), matrix
metalloproteinase inhibitors (marimastat), vascular
endothelial growth factor A inhibitors (bevacizumab),
and histone deacetylase inhibitors (CI-994). However,
most of these trials showed negative results.
In the present analysis, nine trials including 3, 342
patients evaluated gemcitabine combined with targeted
therapy (Table 3). Although the results of the most
recent trials (Philip 2010, Kindler 2010) are now avail-
able, which evaluated gemcitabine combined with C-225
or bevacizumab, so far Moore’s trial is still the only
study to demonstrate a significant improvement in sur-
vival in LA/MPC as a result of adding a targeted agent
to gemcitabine. Therefore, the addition of other targeted
agents is not recommended for the treatment of LA/
MPC in the current clinical setting outside of a clinical
trials.
Trials discussing gemcitabine doublets plus a third
targeted reagent
Two trials (Cascino 2008, Vervenne 2008) including 691
patients evaluated a gemcitabine doublet with or with-
out a third targeted reagent. In Cascino’sm u l t i c e n t e r
randomized phase II trial, the addition of cetuximab to
the gemcitabine/cisplatin combination did not increase
PFS (hazard ratio 0.96, 95% CI, 0.60-1.52, p = 0.847) or
OS (hazard ratio 0.91, 95% CI, 0.54-1.55, p = 0.739). In
2008, Vervenne compared the efficacy and safety of add-
ing bevacizumab to erlotinib and gemcitabine in patients
with metastatic pancreatic cancer. The results showed
that addition of bevacizumab to erlotinib and gemcita-
bine did not significantly prolong OS, but there was a
significant improvement in PFS (p = 0.0002). This com-
bination requires further investigation in larger-scale
clinical trials to assess efficacy and cost effectiveness.
Pooled analysis revealed slightly better disease control
by adding a third reagent to the gemcitabine doublet,
with an ORs of 1.62 (95% CI, 1.00 to 2.62), but this was
Figure 2 Comparison of gemcitabine-X combination with gemcitabine alone. A, OS; B, PFS.
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Page 8 of 15Figure 3 Comparison of gemcitabine plus fluoropyrimidine or platinum with gemcitabine alone on OS and PFS.A ,g e m c i t a b i n e /
fluoropyrimidine versus gemcitabine alone on OS; B, gemcitabine/platinum versus gemcitabine alone on OS; C, gemcitabine/oxaliplatin versus
gemcitabine alone on OS; D, gemcitabine/cisplatin versus gemcitabine alone on OS; E, gemcitabine/platinum versus gemcitabine alone on PFS;
F, gemcitabine/oxaliplatin versus gemcitabine alone on PFS; G, gemcitabine/cisplatin versus gemcitabine alone on PFS.
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Page 9 of 15not statistically significant (p = 0.05). Furthermore, the
O So b s e r v e di nt h et r i p l e tg r o u pw a sd i s a p p o i n t i n g
(ORs, -0.79; 95% CI, -0.90 to -0.60; p < 0.00001).
Discussion
Pancreatic adenocarcinoma is among the most challen-
ging of solid malignancies to treat on account of its pro-
pensity for late presentation with inoperable disease,
aggressive tumor biology and resistance to chemother-
apy [43,44]. Gemcitabine monotherapy has become a
cornerstone of therapy for patients with LA/MPC since
Burris et al reported their phase III trial results.
Although it has shown clinical benefit, gemcitabine
monotherapy has been associated with limited antitumor
activity, with an ORR of 5% and median OS of 5.7
months [5]. In the past decade, many randomized con-
trolled trials evaluated gemcitabine combined with var-
ious cytotoxic or targeted agents to try to improve
outcomes for patients with LA/MPC. Some of these stu-
dies have reported improved median OS and one-year
Figure 4 Comparison of gemcitabine plus platinum combination with gemcitabine alone. A, gemcitabine/platinum versus gemcitabine
alone on 1-year survival; B, gemcitabine/oxaliplatin versus gemcitabine alone on 1-year survival; C, gemcitabine/platinum versus gemcitabine
alone on ORR.
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Page 10 of 15survival rates. However, the question of whether gemci-
tabine-based combinations are better than gemcitabine
monotherapy is still unclear.
To compare the efficacy and tolerability of gemcita-
bine-based combinations in the treatment of LA/MPC
with sufficient statistical power, we performed this
meta-analysis to overcome the statistical limitations (for
instance, low case load) of the individual trials and
investigate treatment efficacy, safety profile and survival
benefit of various therapeutic combinations.
The systematic review yielded five major findings.
First, the analysis showed that gemcitabine-based combi-
nation was associated with significantly greater OS (ORs,
1.15; p = 0.011), PFS (ORs, 1.27; p < 0.001), and ORR
(ORs, 1.58; p < 0.001) than gemcitabine monotherapy.
The study reported by Heinemann revealed similar
results [45]; their study considered 15 trials including
4465 patients for the analysis of OS. The analysis
revealed a significant survival benefit for gemcitabine+X
(X = cytotoxic agent) with a pooled ORs of 0.91 (p =
0.004) and indicated that patients with a good PS had a
marked survival benefit when receiving combination
chemotherapy (ORs, 0.76; p < 0.0001).
A similar advantage for gemcitabine combined with
fluoropyrimidine was observed in terms of the OS (ORs,
1.33; p = 0.007), PFS (ORs, 1.53; p < 0.001), and ORR
(ORs 1.47, p = 0.03) as compared to gemcitabine alone.
Although the occurrence of hematological toxicities,
including neutropenia (ORs, 1.60; p = 0.002) and throm-
bocytopenia (ORs, 1.52; p = 0.04), was higher in the
combination group, the incidence of anemia (ORs, 0.97;
p = 0.90) and non-hematological toxicities such as nau-
sea/vomiting (ORs, 1.10; p = 0.60) were similar in both
groups.
It remained to be determined whether the combination
of gemcitabine with 5-FU or that with capecitabine was
better. Bolus 5-FU and high-dose leucovorin have not
shown meaningful therapeutic benefits in phase II studies
[46]. However, researchers have speculated that continu-
ous-infusion of 5-FU could improve its therapeutic effi-
cacy. Capecitabine (N4-pentyloxycarbonyl-5’-deoxy-5-
fluorocytidine) (Xeloda; F. Hoffmann-La Roche, Basel,
Switzerland), an oral tumor-selective fluoropyrimidine,
has been reported to be as efficacious as continuous-infu-
sion 5-FU. Capecitabine appears to be a reasonable sub-
stitute for infused 5-FU/LV in combination regimens or
as monotherapy, with the added advantage of reducing
the inconvenience of long infusion times [47]. Cartwright
[48] reported that capecitabine alone has an ORR of 7.3%
and a disease control rate of 24% in previously untreated
patients with LA/MPC. In Cunningham’sr e p o r t ,g e m c i -
tabine/capecitabine significantly improved ORR (19.1% v
Figure 5 OS and PFS of gemcitabine/camptothecin combination as compared with gemcitabine in monotherapy. A, OS; B, PFS.
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Page 11 of 1512.4%; p = 0.034) and PFS (hazard ratio, 0.78; 95% CI,
0.66 to 0.93; p = 0.004) and was associated with a trend
toward improved OS (hazard ratio, 0.86; 95% CI, 0.72 to
1.02; p = 0.08) compared with gemcitabine alone. On the
basis of these results, he recommended that gemcitabine/
capecitabine should be considered one of the standard
first-line options in LA/MPC.
In 1993, Wils [49] was the first to report that single-
agent cisplatin has therapeutic activity in LA/MPC with
an ORR of 21%. Soon afterwards, several phase II
studies discussed the gemcitabine plus cisplatin combi-
nation in a variety of schedules. Adding cisplatin to
gemcitabine appeared to be very active, with ORR
ranging from 9% to 31% and median OS from 5.6 to
9.6 months in these phase II trials [50-52]. Furthermore,
in the neoadjuvant setting, Palmer (2007) showed that
combination therapy with gemcitabine and cisplatin was
associated with a high resection rate and an encouraging
survival rate.
However, the pooled analysis showed that the PFS and
ORR achieved with the gemcitabine and platinum combi-
nation were significantly greater than those achieved with
gemcitabine monotherapy; however, no statistically sig-
nificant difference between the 2 treatment approaches
were observed in the case of OS. This result was consis-
tent with that obtained in a study conducted by Bria [4].
In Bria’s meta-analysis, platinum combinations led to the
greater absolute benefits in terms of PFS and ORR as
compared with single-agent gemcitabine (10% and 6.5%,
r e s p e c t i v e l y ) ,b u td i dn o tr e s u l ti na nO Sb e n e f i t .H o w -
ever, Heinemann [45] reported contrary results, with a
ORs of 0.85 (p = 0.010) for platinum-gemcitabine combi-
nations compared to gemcitabine alone. Heinemann’s
study included 15 trials with 4465 patients, whereas
Bria’s study included 20 trials with 6296 patients; our
study included 35 trials with 9979 patients. The greater
number of included trials and case load in our study may
have contributed to the more favorable results obtained
in our study.
Further, our subgroup analysis showed that the OS
(p = 0.019), PFS (p = 0.011), and one-year survival (p =
0.04) in the gemcitabine-oxaliplatin group were signifi-
cantly better than those in the gemcitabine monotherapy
group. On the contrary, the comparison of gemcitabine-
cisplatin with gemcitabine alone showed that there was
no survival benefit (OS: p = 0.93; PFS: p = 0.17) with
the former. Hence, we concluded that the combination
of gemcitabine and oxaliplatin is superior to gemcitabine
plus cisplatin and may be recommended as one of the
standard first-line therapies for LA/MPC.
The third key finding was that the combination of
gemcitabine plus other cytotoxic agents showed disap-
pointing results. According to the literature, the combi-
nation of gemcitabine and irinotecan resulted in an
objective response of 25% with a median OS ranging
from 5.7 to 7 months (Rocha-Lima 2002, Stathopoulos
2004). Although our analysis found an enhanced ORR
for gemcitabine plus camptothecin therapy (ORs, 2.03;
p = 0.003), we did not find a significant difference in OS
(ORs, 1.03; p = 0.82) or PFS (ORs, 0.97; p = 0.78) in the
comparison. Other single agents including docetaxel and
pemetrexed have also been tested in advanced
Table 3 Median OS and DFS in trials comparing gemcitabine combined with targeted therapy with gemcitabine alone
Trial Regimen
(per arm)
No. of
pts
Median OS (mons) HR (95% CI) p value Median PFS/TTP (mons) HR (95%CI) p value
Moore MJ 2007 Gem/erlotinib 285 6.24 0.82 0.038* 3.75 0.77 0 .004*
Gem 284 5.91 (0.69-0.99) 3.55 (0.64-0.92)
Philip A 2010 Gem/C-225 372 6.3 1.06 0 .23 3.4 1.07 0.18
Gem 371 5.9 (0.91-1.23) 3.0 (0.93-1.24)
Van Cutsem E 2004 Gem/tipifarnib 341 6.4 1.03 0 .75 3.7 1.03 0 .72
Gem 347 6.1 (0.86-1.23) 3.6 (0.87-1.22)
Saif W 2009 Gem/LY293111 67 7.1 UA > 0.05 3.7 UA > 0.05
Gem 66 8.3 3.4
Spano JP 2008 Gem/axitinib 69 6.9 0·71 UA 4.2 UA
Gem 34 5.6 (0.44-1.13) 3.7 (0.43-1.45)
Bramhall SR 2002 Gem/marimastat 120 5.5 0.99 0.95 3.1 0.68 0.68
Gem 119 5.5 (0.76-1.30) 3.2 (0.73-1.23)
Kindler HL 2010 Gem/bevacizumab 302 5.8 1.004 0.95 3.8 UA 0.075
Bev 300 5.9 (0.88-1.24) 2.9
Richards DA 2006 Gem/CI-994 85 6.5 0.980 0.904 3.1 0.837 0.304
Gem 88 7.1 (0.701-1.370) 3.4 (0.596-1.175)
Friess H 2006 Gem/cilengitide 46 6.8 UA > 0.05 3.7 UA > 0.05
Gem 43 7.8 3.8
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Page 12 of 15pancreatic cancer. However, the analysis of two trials (n
= 665) showed negative results. The OS in the combina-
tion group was even lower than that of patients receiv-
ing monotherapy (ORs, -0.10; p = 0.002), although the
ORR analysis showed therapeutic benefit for this combi-
nation group (ORs, 1.91; p = 0.01).
Fourth, the identification of novel targets is still elu-
sive for the treatment of LA/MPC. Since 2002, there has
been a series of disappointing results. The only excep-
tion is erlotinib, which is the first and only targeted
agent to demonstrate significantly improved survival in
advanced pancreatic cancer when added to gemcitabine.
Further research should be focused on new combina-
tions or multi-target combined therapy, incorporating
new, targeted therapies and identifying potential predic-
tive factors of response.
The fifth finding concerned combining a gemcitabine
doublet with or without a third targeted reagent. Our
analysis revealed slightly better disease control by adding
a third reagent to a gemcitabine doublet, with an ORs of
1.62 (95% CI, 1.00 to 2.62), but this difference was not
statistically significant (p = 0.05). The OS in the triplet
group was also disappointing (ORs, -0.79; p < 0.00001).
Vervenne’s study showed that addition of bevacizumab
to erlotinib and gemcitabine did not significantly pro-
long OS, but there was a significant improvement in
P F S( p=0 . 0 0 0 2 ) .T h i ss u g g e s t e dt h a tm u l t i - t a r g e tt h e r -
apy may be a future direction for the treatment of
advanced pancreatic cancer. This combination should be
further evaluated in larger clinical trials to assess its effi-
cacy and cost effectiveness.
The present meta-analysis was not based on individual
patient data and was not subjected to an open external-
evaluation procedure. Therefore, the analysis is limited
in that the use of published data may have led to an
overestimation of the treatment effects. Although the
risk of publication bias exists in any meta-analysis, we
believe that this did not greatly affect our results
because many positive and negative trials were included
in the study.
Moreover, some trials investigated gemcitabine-free
combinations such as irinotecan/docetaxel or FOLFIRI-
NOX for the treatment of LA/MPC. Among them, FOL-
FIRINOX (5-FU/leucovorin, irinotecan, and oxaliplatin)
is an interesting and promising combination. At the
2007 ASCO annual meeting, Ychou reported that the
use of FOLFIRINOX as the first-line treatment for
advanced pancreatic cancer afforded a response rate of
greater than 30% with manageable toxicity in ECOG 0-1
patients [53]. In another study, Breysacher discussed the
role of FOLFIRINOX as second-line therapy for meta-
static pancreatic cancer [54]. No response was seen in
13 patients, and the one-year survival rate was 62%.
However, a large-scale randomized clinical trial is
required to evaluate the efficacy of FOLFIRINOX.
In the end, the goals of treatment for advanced pancrea-
tic cancer should be to control tumor progression, allevi-
ate disease-related symptoms and improve and maintain
patients’ quality of life (QOL). Reni [55] reported on the
effects of a gemcitabine combination versus monotherapy
on patient QOL. The study showed that the largest differ-
ences between arms favored the gemcitabine combination
group. Clinically relevant improvement in QOL from
baseline was observed more often after combination ther-
apy than after gemcitabine, suggesting that the combina-
tion regimen did not impair QOL.
Conclusion
In general, the benefits of adding capecitabine or oxali-
platin to gemcitabine chemotherapy in LA/MPC are
clear, with prolonged survival, improvement in disease
control and improvement or stabilization of QOL as
compared with gemcitabine monotherapy.
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